Eliem Therapeutics Long Term Debt

As of the most recent data (June 2026), ELYM shows a long-term debt of $810K. That compares with $420K in the prior-year period — up 95.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ELYM's long-term debt is now $810K (was $420K) — a 95.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Eliem Therapeutics is outperforming or lagging.

Tracking ELYM's long-term debt over time shows whether Eliem Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $810K That compares with $420K in the prior-year period — up 95.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Eliem Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $810K) with ownership activity and broader fundamentals.

Eliem Therapeutics's long-term debt is $810K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.